Characterization of myelodysplastic syndrome and aplastic anemia by immunostaining of p53 and hemoglobin F and karyotype analysis: Differential diagnosis between refractory anemia and aplastic anemia

Takashi Iwasaki, Masashi Murakami, Chiho Sugisaki, Sayaka Sobue, Haruhiko Ohashi, Haruhiko Asano, Motoshi Suzuki, Shigeo Nakamura, Masafumi Ito, Takashi Murate

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

P53 mutation has been reported in various solid tumors, acute leukemia and myelodysplastic syndrome (MDS), but the diagnostic significance of p53 in MDS remains to be determined. The purpose of the present paper was to examine p53 mutation and immunostaining of the same patients, because there have been few reports of simultaneous analysis of these markers. Seven p53 mutations were observed among 37 MDS and 11 cases of overt leukemia transformed from MDS (MDS-OL). Mutated p53 mainly observed in high-risk MDS had more intense p53 staining than in MDS with wild-type p53 overexpression. Aplastic anemia (AA) produced no p53 staining. The percentage of p53 staining in MDS (71%) was higher than that of mutated p53 (11%) but did not reach 100% of MDS cases studied, therefore the authors attempted to differentiate MDS, especially refractory anemia (RA) and AA, using a combination of p53 immunostaining, hemoglobin F (HbF) immunostaining and chromosome abnormality, because HbF of erythroblasts was reportedly observed in MDS RA but not in AA. Most MDS/MDS-OL (47/48) had at least one positive marker. Among 11 AA cases, only two were positive for HbF. The present results suggest that the combination of these three markers is useful to discriminate MDS from AA.

Original languageEnglish
Pages (from-to)353-360
Number of pages8
JournalPathology International
Volume58
Issue number6
DOIs
Publication statusPublished - 01-06-2008
Externally publishedYes

Fingerprint

Refractory Anemia
Fetal Hemoglobin
Aplastic Anemia
Myelodysplastic Syndromes
Karyotype
Differential Diagnosis
Staining and Labeling
Mutation
Leukemia
Erythroblasts

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

Iwasaki, Takashi ; Murakami, Masashi ; Sugisaki, Chiho ; Sobue, Sayaka ; Ohashi, Haruhiko ; Asano, Haruhiko ; Suzuki, Motoshi ; Nakamura, Shigeo ; Ito, Masafumi ; Murate, Takashi. / Characterization of myelodysplastic syndrome and aplastic anemia by immunostaining of p53 and hemoglobin F and karyotype analysis : Differential diagnosis between refractory anemia and aplastic anemia. In: Pathology International. 2008 ; Vol. 58, No. 6. pp. 353-360.
@article{f044be4688b542faaa4c740ef2c925f8,
title = "Characterization of myelodysplastic syndrome and aplastic anemia by immunostaining of p53 and hemoglobin F and karyotype analysis: Differential diagnosis between refractory anemia and aplastic anemia",
abstract = "P53 mutation has been reported in various solid tumors, acute leukemia and myelodysplastic syndrome (MDS), but the diagnostic significance of p53 in MDS remains to be determined. The purpose of the present paper was to examine p53 mutation and immunostaining of the same patients, because there have been few reports of simultaneous analysis of these markers. Seven p53 mutations were observed among 37 MDS and 11 cases of overt leukemia transformed from MDS (MDS-OL). Mutated p53 mainly observed in high-risk MDS had more intense p53 staining than in MDS with wild-type p53 overexpression. Aplastic anemia (AA) produced no p53 staining. The percentage of p53 staining in MDS (71{\%}) was higher than that of mutated p53 (11{\%}) but did not reach 100{\%} of MDS cases studied, therefore the authors attempted to differentiate MDS, especially refractory anemia (RA) and AA, using a combination of p53 immunostaining, hemoglobin F (HbF) immunostaining and chromosome abnormality, because HbF of erythroblasts was reportedly observed in MDS RA but not in AA. Most MDS/MDS-OL (47/48) had at least one positive marker. Among 11 AA cases, only two were positive for HbF. The present results suggest that the combination of these three markers is useful to discriminate MDS from AA.",
author = "Takashi Iwasaki and Masashi Murakami and Chiho Sugisaki and Sayaka Sobue and Haruhiko Ohashi and Haruhiko Asano and Motoshi Suzuki and Shigeo Nakamura and Masafumi Ito and Takashi Murate",
year = "2008",
month = "6",
day = "1",
doi = "10.1111/j.1440-1827.2008.02236.x",
language = "English",
volume = "58",
pages = "353--360",
journal = "Pathology International",
issn = "1320-5463",
publisher = "Wiley-Blackwell",
number = "6",

}

Characterization of myelodysplastic syndrome and aplastic anemia by immunostaining of p53 and hemoglobin F and karyotype analysis : Differential diagnosis between refractory anemia and aplastic anemia. / Iwasaki, Takashi; Murakami, Masashi; Sugisaki, Chiho; Sobue, Sayaka; Ohashi, Haruhiko; Asano, Haruhiko; Suzuki, Motoshi; Nakamura, Shigeo; Ito, Masafumi; Murate, Takashi.

In: Pathology International, Vol. 58, No. 6, 01.06.2008, p. 353-360.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Characterization of myelodysplastic syndrome and aplastic anemia by immunostaining of p53 and hemoglobin F and karyotype analysis

T2 - Differential diagnosis between refractory anemia and aplastic anemia

AU - Iwasaki, Takashi

AU - Murakami, Masashi

AU - Sugisaki, Chiho

AU - Sobue, Sayaka

AU - Ohashi, Haruhiko

AU - Asano, Haruhiko

AU - Suzuki, Motoshi

AU - Nakamura, Shigeo

AU - Ito, Masafumi

AU - Murate, Takashi

PY - 2008/6/1

Y1 - 2008/6/1

N2 - P53 mutation has been reported in various solid tumors, acute leukemia and myelodysplastic syndrome (MDS), but the diagnostic significance of p53 in MDS remains to be determined. The purpose of the present paper was to examine p53 mutation and immunostaining of the same patients, because there have been few reports of simultaneous analysis of these markers. Seven p53 mutations were observed among 37 MDS and 11 cases of overt leukemia transformed from MDS (MDS-OL). Mutated p53 mainly observed in high-risk MDS had more intense p53 staining than in MDS with wild-type p53 overexpression. Aplastic anemia (AA) produced no p53 staining. The percentage of p53 staining in MDS (71%) was higher than that of mutated p53 (11%) but did not reach 100% of MDS cases studied, therefore the authors attempted to differentiate MDS, especially refractory anemia (RA) and AA, using a combination of p53 immunostaining, hemoglobin F (HbF) immunostaining and chromosome abnormality, because HbF of erythroblasts was reportedly observed in MDS RA but not in AA. Most MDS/MDS-OL (47/48) had at least one positive marker. Among 11 AA cases, only two were positive for HbF. The present results suggest that the combination of these three markers is useful to discriminate MDS from AA.

AB - P53 mutation has been reported in various solid tumors, acute leukemia and myelodysplastic syndrome (MDS), but the diagnostic significance of p53 in MDS remains to be determined. The purpose of the present paper was to examine p53 mutation and immunostaining of the same patients, because there have been few reports of simultaneous analysis of these markers. Seven p53 mutations were observed among 37 MDS and 11 cases of overt leukemia transformed from MDS (MDS-OL). Mutated p53 mainly observed in high-risk MDS had more intense p53 staining than in MDS with wild-type p53 overexpression. Aplastic anemia (AA) produced no p53 staining. The percentage of p53 staining in MDS (71%) was higher than that of mutated p53 (11%) but did not reach 100% of MDS cases studied, therefore the authors attempted to differentiate MDS, especially refractory anemia (RA) and AA, using a combination of p53 immunostaining, hemoglobin F (HbF) immunostaining and chromosome abnormality, because HbF of erythroblasts was reportedly observed in MDS RA but not in AA. Most MDS/MDS-OL (47/48) had at least one positive marker. Among 11 AA cases, only two were positive for HbF. The present results suggest that the combination of these three markers is useful to discriminate MDS from AA.

UR - http://www.scopus.com/inward/record.url?scp=43549109501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43549109501&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1827.2008.02236.x

DO - 10.1111/j.1440-1827.2008.02236.x

M3 - Article

C2 - 18477214

AN - SCOPUS:43549109501

VL - 58

SP - 353

EP - 360

JO - Pathology International

JF - Pathology International

SN - 1320-5463

IS - 6

ER -